{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:07:34Z","timestamp":1785820054268,"version":"3.56.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016949","name":"Tenax Therapeutics Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016949","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cardfail.2025.06.009","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T11:16:12Z","timestamp":1751886972000},"page":"1059-1071","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Oral Levosimendan for the Treatment of Pulmonary Hypertension due to Heart Failure With Preserved Ejection Fraction: Rationale and Design of the LEVEL Trial"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1011-1033","authenticated-orcid":false,"given":"HIDENORI","family":"YAKU","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DANIEL","family":"BURKHOFF","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BARRY A.","family":"BORLAUG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANURADHA","family":"LALA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JAVED","family":"BUTLER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"STUART","family":"RICH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5655-8201","authenticated-orcid":false,"given":"SANJIV J.","family":"SHAH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2025.06.009_bib0001","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1161\/CIR.0000000000001079","article-title":"Elucidating the clinical implications and pathophysiology of pulmonary hypertension in heart failure with preserved ejection fraction: a call to action: a science advisory from the American Heart Association","volume":"146","author":"Brittain","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0002","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.hlc.2016.09.004","article-title":"Pilot study of endothelin receptor blockade in heart failure with diastolic dysfunction and pulmonary hypertension (BADDHY-trial)","volume":"26","author":"Koller","year":"2017","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0003","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1093\/eurheartj\/ehac389","article-title":"Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial","volume":"43","author":"Dachs","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0004","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/eurheartj\/ehv336","article-title":"Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial","volume":"36","author":"Hoendermis","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0005","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01886-2017","article-title":"Macitentan in pulmonary hypertension due to left ventricular dysfunction","volume":"51","author":"Vachi\u00e9ry","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0006","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1161\/CIRCULATIONAHA.124.069340","article-title":"Tadalafil for treatment of combined postcapillary and precapillary pulmonary hypertension in patients with heart failure and preserved ejection fraction: a randomized controlled phase 3 study","volume":"150","author":"Hoeper","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0007","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC Scientific Statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0008","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/ejhf.2254","article-title":"Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction","volume":"23","author":"Sorimachi","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0009","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1161\/CIRCULATIONAHA.117.031608","article-title":"Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction","volume":"137","author":"Fayyaz","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0010","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1093\/eurheartj\/ehu193","article-title":"Right heart dysfunction in heart failure with preserved ejection fraction","volume":"35","author":"Melenovsky","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0011","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/eurheartj\/ehy809","article-title":"Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction","volume":"40","author":"Obokata","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0012","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijcard.2011.07.022","article-title":"Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan","volume":"159","author":"Papp","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0013","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1002\/ehf2.13669","article-title":"Levosimendan-induced venodilation is mediated by opening of potassium channels","volume":"8","author":"Burkhoff","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0014","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/jamacardio.2024.2612","article-title":"Endovascular ablation of the greater splanchnic nerve in heart failure with preserved ejection fraction: the REBALANCE-HF randomized clinical trial","volume":"9","author":"Fudim","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0015","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0735-1097(00)00961-X","article-title":"Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure","volume":"36","author":"Nieminen","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0016","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jchf.2021.01.015","article-title":"Levosimendan improves hemodynamics and exercise tolerance in PH-HFpEF: results of the randomized placebo-controlled HELP trial","volume":"9","author":"Burkhoff","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0017","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.cardfail.2021.05.022","article-title":"Changes in stressed blood volume with levosimendan in pulmonary hypertension from heart failure with preserved ejection fraction: insights regarding mechanism of action from the HELP trial","volume":"27","author":"Brener","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0018","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.15420\/cfr.2020.03","article-title":"Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use","volume":"6","author":"Papp","year":"2020","journal-title":"Card Fail Rev"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0019","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cardfail.2022.10.420","article-title":"The transition from chronic intravenous to oral levosimendan is safe and effective in patients with pulmonary hypertension with heart failure and preserved ejection fraction","volume":"29","author":"Thenappan","year":"2023","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0020","first-page":"141","article-title":"An empirical transition matrix for non-homogeneous markov chains based on censored observations","volume":"5","author":"Aalen","year":"1978","journal-title":"Scand J Statist"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0021","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.0006-341X.2000.00554.x","article-title":"Nonparametric analysis of recurrent events and death","volume":"56","author":"Ghosh","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0022","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/ejhf.3236","article-title":"A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function","volume":"26","author":"Ameri","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0023","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","article-title":"Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial","volume":"360","author":"Follath","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0024","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","article-title":"Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial","volume":"297","author":"Mebazaa","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0025","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ejhf.1145","article-title":"Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial","volume":"20","author":"Com\u00edn-Colet","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0026","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1002\/ehf2.13670","article-title":"Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study","volume":"8","author":"Garc\u00eda-Gonz\u00e1lez","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0027","first-page":"103","article-title":"Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure","volume":"1","author":"Packer","year":"2013","journal-title":"JACC: Heart Fail"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0028","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.ejheart.2008.09.006","article-title":"Oral levosimendan in patients with severe chronic heart failure: the PERSIST study","volume":"10","author":"Nieminen","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0029","first-page":"459","article-title":"Prognostic significance and determinants of the 6-min walk test in patients with heart failure and preserved ejection fraction","volume":"3","author":"Zotter-Tufaro","year":"2015","journal-title":"JACC: Heart Fail"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0030","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/ehf2.15203","article-title":"Relaxin mimetic in pulmonary hypertension associated with left heart disease: design and rationale of Re-PHIRE","volume":"12","author":"Ufnal","year":"2025","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cardfail.2025.06.009_bib0031","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/14017431.2011.557779","article-title":"Oral levosimendan improves filling pressure and systolic function during long-term treatment","volume":"45","author":"Jalanko","year":"2011","journal-title":"Scand Cardiovasc J"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916425002933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916425002933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:55:42Z","timestamp":1781002542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916425002933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1071916425002933"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2025.06.009","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Levosimendan for the Treatment of Pulmonary Hypertension due to Heart Failure With Preserved Ejection Fraction: Rationale and Design of the LEVEL Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2025.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}